---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-266770"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2026-06-11T13:00:07+00:00"
generated_at: "2026-06-11T13:01:14.319178+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health secures up to $40M equity line and $2M preferred stock financing

## Summary
- ELOC agreement provides up to $40M of common stock purchases; floor price set at $1.10 per share.
- Single fixed purchase capped at $1.5M; $800K commitment shares to be issued upon registration effectiveness.
- Series P preferred stock financing: 240 shares at $10K stated value, 8% annual dividend, mandatory redemption with ELOC proceeds.
- Stockholder approval obtained June 8, 2026 allowing issuances beyond 19.99% for both facilities.
- Proceeds intended for general corporate purposes; registration statements to be filed within 30 days.

## SEC filing metadata
- accession: 0001193125-26-266770
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2026-06-11T13:00:07+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000119312526266770/0001193125-26-266770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000119312526266770/d570985d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-266770
- JSON: https://secwatch.observer/filing/0001193125-26-266770.json
- Plain text: https://secwatch.observer/filing/0001193125-26-266770.txt

## Key facts
- Equity Issuances
  Jaguar Health, Inc. issued common stock to Institutional Investor.
  - Security: common stock
  - Purchaser: Institutional Investor
  source text: In consideration for the Institutional Investor’s execution and delivery of the ELOC Agreement, the Company agreed to issue to the Institutional Investor on the effective date of the ELOC Registration Statement (as defined hereunder) $800,000 worth of the Company’s Common Stock, valued at the VWAP Purchase Price as of such effective date (the “Commitment Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1585608/000119312526266770/0001193125-26-266770-index.htm
- Governance Changes
  Jaguar Health, Inc.: Filed Series P Certificate of Designation with Delaware Secretary of State on June 8, 2026, effective upon filing, authorizing up to 300 shares of Series P Preferred Stock with specific dividend, voting, and liquidation preferences (effective 2026-06-08).
  - Change: charter amendment
  - Effective: 2026-06-08
  source text: The preferences, rights, limitations and other matters relating to the Series P Preferred Stock are set forth in the Certificate of Designation, which the Company filed with the Secretary of State of the State of Delaware on June 8, 2026. The Certificate of Designation became effective with the Secretary of State of the State of Delaware upon filing. The Certificate of Designation authorizes the Company to issue up to 300 of its 4,475,074 authorized shares of preferred stock as Series P Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1585608/000119312526266770/0001193125-26-266770-index.htm
- Material Agreements
  Jaguar Health, Inc. entered into common stock purchase agreement with an accredited investor valued at up to an aggregate of $40 million (effective 2026-06-09).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an accredited investor
  - Value: up to an aggregate of $40 million
  - Effective: 2026-06-09
  source text: On June 9, 2026, Jaguar Health, Inc. (the “Company”) entered into a common stock purchase agreement (the “ELOC Agreement”) with an accredited investor (the “Institutional Investor”), which provides that, upon the terms and subject to the conditions set forth therein, the Institutional Investor is committed to purchase up to an aggregate of $40 million of shares of Common Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1585608/000119312526266770/0001193125-26-266770-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.